• Cyclerion posted a net loss of $3.18 million for three months ended March 31, 2026, widening 122%.
• No revenue was reported, swinging from $81,000.
• Research and development expense climbed to $730,000 from $36,000, while general and administrative costs rose 65% to $2.48 million.
• Cash and cash equivalents totaled $2.8 million at March 31, 2026; management said cash should fund operations into third quarter of 2026 and flagged substantial doubt about going concern.
• Cyclerion entered a merger agreement with Korsana on April 1, 2026, targeting a third-quarter close alongside a $380 million Korsana pre-closing financing and a CVR tied to monetization of legacy assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclerion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-219478), on May 12, 2026, and is solely responsible for the information contained therein.